TY - JOUR
T1 - Simultaneous electrical detection of IL-6 and PCT using a microfluidic biochip platform
AU - Berger, Jacob
AU - Valera, Enrique
AU - Jankelow, Aaron
AU - Garcia, Carlos
AU - Akhand, Manik
AU - Heredia, John
AU - Ghonge, Tanmay
AU - Liu, Cynthia
AU - Font-Bartumeus, Victor
AU - Oshana, Gina
AU - Tiao, Justin
AU - Bashir, Rashid
N1 - Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Sepsis, a life-threatening organ dysfunction caused by a dysregulated host response, leads the U.S in both mortality rate and cost of treatment. Sepsis treatment protocols currently rely on broad and non-specific parameters like heart and respiration rate, and temperature; however, studies show that biomarkers Interlukin-6 (IL-6) and Procalcitonin (PCT) correlate to sepsis progression and response to treatment. Prior work also suggests that using multi-parameter predictive analytics with biomarkers and clinical information can inform treatment to improve outcome. A point-of-care (POC) platform that provides information for multiple biomarkers can aid in the diagnosis and prognosis of potentially septic patients. Using impedance cytometry, microbead immunoassays, and biotin-streptavidin binding, we report a microfluidic POC system that correlates microbead capture to IL-6 and PCT concentrations. A multiplexed microbead immunoassay is developed and validated for simultaneous detection of both IL-6 and PCT from human plasma samples. Using the POC platform, we quantified plasma samples containing healthy, medium (~103pg/ml) and high (~105pg/ml) IL-6 and PCT concentrations with various levels of significance (P < 0.05-P < 0.00001) and validated the concept of this device as a POC platform for sepsis biomarkers.
AB - Sepsis, a life-threatening organ dysfunction caused by a dysregulated host response, leads the U.S in both mortality rate and cost of treatment. Sepsis treatment protocols currently rely on broad and non-specific parameters like heart and respiration rate, and temperature; however, studies show that biomarkers Interlukin-6 (IL-6) and Procalcitonin (PCT) correlate to sepsis progression and response to treatment. Prior work also suggests that using multi-parameter predictive analytics with biomarkers and clinical information can inform treatment to improve outcome. A point-of-care (POC) platform that provides information for multiple biomarkers can aid in the diagnosis and prognosis of potentially septic patients. Using impedance cytometry, microbead immunoassays, and biotin-streptavidin binding, we report a microfluidic POC system that correlates microbead capture to IL-6 and PCT concentrations. A multiplexed microbead immunoassay is developed and validated for simultaneous detection of both IL-6 and PCT from human plasma samples. Using the POC platform, we quantified plasma samples containing healthy, medium (~103pg/ml) and high (~105pg/ml) IL-6 and PCT concentrations with various levels of significance (P < 0.05-P < 0.00001) and validated the concept of this device as a POC platform for sepsis biomarkers.
KW - IL-6 and PCT
KW - Micro-bead assay
KW - Microfluidic electrical impedance
KW - Point-of-care diagnostics
KW - Protein detection
KW - Sepsis
UR - http://www.scopus.com/inward/record.url?scp=85084871632&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084871632&partnerID=8YFLogxK
U2 - 10.1007/s10544-020-00492-6
DO - 10.1007/s10544-020-00492-6
M3 - Article
C2 - 32419087
AN - SCOPUS:85084871632
SN - 1387-2176
VL - 22
JO - Biomedical microdevices
JF - Biomedical microdevices
IS - 2
M1 - 36
ER -